BR112022011158A2 - Vírus vaccinia oncolítico variante e métodos de uso do mesmo - Google Patents

Vírus vaccinia oncolítico variante e métodos de uso do mesmo

Info

Publication number
BR112022011158A2
BR112022011158A2 BR112022011158A BR112022011158A BR112022011158A2 BR 112022011158 A2 BR112022011158 A2 BR 112022011158A2 BR 112022011158 A BR112022011158 A BR 112022011158A BR 112022011158 A BR112022011158 A BR 112022011158A BR 112022011158 A2 BR112022011158 A2 BR 112022011158A2
Authority
BR
Brazil
Prior art keywords
variant
polypeptide
vaccinia virus
oncolytic vaccinia
ovv
Prior art date
Application number
BR112022011158A
Other languages
English (en)
Inventor
Michael Abbadessa Darin
Maruri Avidal Liliana
Phillip Gulizia Nathaniel
H Kirn David
A Kotterman Melissa
Brandon Slaby Todd
Original Assignee
Ignite Immunotherapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignite Immunotherapy Inc filed Critical Ignite Immunotherapy Inc
Publication of BR112022011158A2 publication Critical patent/BR112022011158A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

VÍRUS VACCINIA ONCOLÍTICO VARIANTE E MÉTODOS DE USO DO MESMO. A presente invenção refere-se a um vírus Vaccinia oncolítico recombinante (OVV) competente para replicação compreendendo um ou mais dentre a) uma sequência de nucleotídeos que codifica um polipeptídeo A33 variante, b) uma sequência de nucleotídeos que codifica um polipeptídeo A34 variante e c) uma sequência de nucleotídeos que codifica um polipeptídeo B5 variante, em que os polipeptídeos A33 variante, A34 variante e B5 variantes compreendem uma ou mais substituições de aminoácidos que proporcionam uma propagação viral aumentada ou uma produção aumentada de EEV em comparação a um vírus que codifica um polipeptídeo A33, A34 e B5 do tipo selvagem correspondente. A presente invenção também fornece composições compreendendo o OVV e o uso do OVV ou da composição para indução de oncólise em um indivíduo com um tumor.
BR112022011158A 2019-12-12 2020-12-09 Vírus vaccinia oncolítico variante e métodos de uso do mesmo BR112022011158A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962947202P 2019-12-12 2019-12-12
US201962947204P 2019-12-12 2019-12-12
US201962947200P 2019-12-12 2019-12-12
PCT/IB2020/061707 WO2021116943A1 (en) 2019-12-12 2020-12-09 Variant oncolytic vaccinia virus and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022011158A2 true BR112022011158A2 (pt) 2022-08-30

Family

ID=73839063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011158A BR112022011158A2 (pt) 2019-12-12 2020-12-09 Vírus vaccinia oncolítico variante e métodos de uso do mesmo

Country Status (11)

Country Link
US (1) US20230002740A1 (pt)
EP (1) EP4073088A1 (pt)
JP (1) JP2021106576A (pt)
KR (1) KR20220113467A (pt)
CN (1) CN115380041A (pt)
AU (1) AU2020402303A1 (pt)
BR (1) BR112022011158A2 (pt)
CA (1) CA3163805A1 (pt)
IL (1) IL293627A (pt)
MX (1) MX2022007237A (pt)
WO (1) WO2021116943A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115607678A (zh) * 2021-07-13 2023-01-17 杭州阿诺生物医药科技有限公司 用于治疗癌症的组合疗法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW197439B (pt) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
JP4796299B2 (ja) * 2002-08-12 2011-10-19 ジェンネレックス インコーポレイティッド ポックスウイルスおよび癌に関する方法および組成物
BRPI0411526A (pt) 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
WO2011125469A1 (ja) 2010-04-09 2011-10-13 国立大学法人東京大学 マイクロrna制御組換えワクシニアウイルス及びその使用
DK3036329T3 (da) * 2013-08-22 2021-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Immunonkolytiske terapier
CN105765062B (zh) 2013-11-21 2020-12-11 国立大学法人鸟取大学 丝裂原活化蛋白激酶依赖性重组痘苗病毒(md-rvv)及其应用
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
AU2016320355B2 (en) * 2015-09-08 2020-10-08 Sillajen, Inc. Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof
JP7551496B2 (ja) * 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター

Also Published As

Publication number Publication date
CA3163805A1 (en) 2021-06-17
WO2021116943A1 (en) 2021-06-17
AU2020402303A1 (en) 2022-06-09
CN115380041A (zh) 2022-11-22
IL293627A (en) 2022-08-01
JP2021106576A (ja) 2021-07-29
EP4073088A1 (en) 2022-10-19
MX2022007237A (es) 2022-07-13
KR20220113467A (ko) 2022-08-12
US20230002740A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
BR112017027448A2 (pt) vacina contra rsv
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
CO2022016156A2 (es) Redirección del tropismo de las cápsides de aav
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
AR114445A1 (es) Conjugados de il-15, y sus usos
CO6210754A2 (es) Vectores de virus oncoliticos de viruela
CO6210761A2 (es) Vectores de virus oncoliticos de viruela
EP4043021A3 (en) Oncolytic tumor viruses and methods of use
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
BR112017019625A2 (pt) udp-glicosiltransferases
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
BR112022011158A2 (pt) Vírus vaccinia oncolítico variante e métodos de uso do mesmo
BR112022025352A2 (pt) Polipeptídeo da gb do citomegalovírus humano
BR112022012324A2 (pt) Composições e métodos para modular simultaneamente expressão de genes
BR112017001463A2 (pt) célula hospedeira melhorada para produzir proteínas
BR112022006926A2 (pt) Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2)
CR20220501A (es) Composiciones y métodos para la inducción de una respuesta inmune
BR112021025031A2 (pt) Terapia de combinação de adenovírus oncolítico e inibidor de checkpoint
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico
BR112015032556A2 (pt) Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico
CO2021009575A2 (es) Composiciones y métodos para la administración de polipéptidos cftr

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: IGNITE IMMUNOTHERAPY, INC. (US)

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]